TY - JOUR
T1 - Disposition of vancomycin during hemofiltration
AU - Matzke, Gary R.
AU - O'Connell, Mary Beth
AU - Collins, Allan J.
AU - Keshaviah, Prakash R.
PY - 1986/10
Y1 - 1986/10
N2 - The disposition of vancomycin was assessed in five patients receiving hemofiltration after intravenous dosing with an 18 mg/kg dose after a hemofiltration procedure. The serum concentration-time profile was characterized before, during, and after the next hemofiltration procedure. The t 1 2 of vancomycin was 136.0 ± 27.2 hours (mean ± SD) before hemofiltration and 4.1 ± 1.2 during hemofiltration. Approximately 400 mg of vancomycin was recovered in the filtrate and the hemofiltration clearance was 152.6 ± 21.5 ml/min. A significant relationship was observed between vancomycin clearance and ultrafiltration flow rate (r = 0.9914). A marked rebound in vancomycin serum concentration (52.4% ± 15.6%) was observed in all patients. Hemofiltration has a significant effect on the disposition of vancomycin. Because of the marked interpatient variability in elimination t 1 2 and the degree and time course of the rebound, an individualized approach to vancomycin therapy in this patient population is recommended.
AB - The disposition of vancomycin was assessed in five patients receiving hemofiltration after intravenous dosing with an 18 mg/kg dose after a hemofiltration procedure. The serum concentration-time profile was characterized before, during, and after the next hemofiltration procedure. The t 1 2 of vancomycin was 136.0 ± 27.2 hours (mean ± SD) before hemofiltration and 4.1 ± 1.2 during hemofiltration. Approximately 400 mg of vancomycin was recovered in the filtrate and the hemofiltration clearance was 152.6 ± 21.5 ml/min. A significant relationship was observed between vancomycin clearance and ultrafiltration flow rate (r = 0.9914). A marked rebound in vancomycin serum concentration (52.4% ± 15.6%) was observed in all patients. Hemofiltration has a significant effect on the disposition of vancomycin. Because of the marked interpatient variability in elimination t 1 2 and the degree and time course of the rebound, an individualized approach to vancomycin therapy in this patient population is recommended.
UR - http://www.scopus.com/inward/record.url?scp=0022537795&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0022537795&partnerID=8YFLogxK
U2 - 10.1038/clpt.1986.201
DO - 10.1038/clpt.1986.201
M3 - Article
C2 - 3757406
AN - SCOPUS:0022537795
SN - 0009-9236
VL - 40
SP - 425
EP - 429
JO - Clinical pharmacology and therapeutics
JF - Clinical pharmacology and therapeutics
IS - 4
ER -